NEW YORK (GenomeWeb) – A recent study led by researchers from Integrated Diagnostics sheds light on the clinical utility of the company's proteomic Xpresys Lung cancer test for evaluating indeterminate pulmonary nodules.
NEW YORK (GenomeWeb) – A recent study led by researchers from Integrated Diagnostics sheds light on the clinical utility of the company's proteomic Xpresys Lung cancer test for evaluating indeterminate pulmonary nodules.
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.